Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

KMT9 controls growth and stemness of colorectal cancer [ChIP-seq]

ABSTRACT: KMT9 controls growth and stemness of colorectal cancer [ChIP-seq]

PROVIDER: PRJNA632609 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12502620_1.fastq.gz	Fastqsanger.gz
	SRR12502620_2.fastq.gz	Fastqsanger.gz
	SRR12502621_1.fastq.gz	Fastqsanger.gz
	SRR12502621_2.fastq.gz	Fastqsanger.gz
	SRR12502622_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

KMT9 controls growth and stemness of colorectal cancer

Project description:KMT9 controls growth and stemness of colorectal cancer

| PRJNA632605 | ENA

KMT9 controls growth and stemness of colorectal cancer [RNA-Seq]

Project description:KMT9 controls growth and stemness of colorectal cancer [RNA-Seq]

| PRJNA632610 | ENA

KMT9 controls growth and stemness of colorectal cancer [single-cell RNA-seq]

Project description:KMT9 controls growth and stemness of colorectal cancer [single-cell RNA-seq]

| PRJNA632611 | ENA

KMT9 controls growth and stemness of colorectal cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-11-29 | GSE150506 | GEO

KMT9 controls growth and stemness of colorectal cancer [RNA-Seq]

Project description:The aim of the study is to identify KMT9α target genes in AOM/DSS tumour organoids, APK and APKK organoids, patient derived CRC organoids, AOM/DSS mouse tumours and normal mouse colon

2021-11-29 | GSE150503 | GEO

KMT9 controls growth and stemness of colorectal cancer [ChIP-seq]

Project description:The aim of the study is to identify KMT9a target genes in AOMDSS tumour organoids

2021-11-29 | GSE150502 | GEO

ATF6 promotes colorectal cancer growth and stemness by regulating the Wnt pathway

Project description:The unfolded protein response (UPR) maintains endoplasmic reticulum (ER) homeostasis by sensing protein-folding stress and orchestrating cellular adaptation via the ER-transmembrane proteins IRE1, PERK and ATF6. Malignant cells can co-opt UPR signaling by IRE1 and PERK to sustain tumor growth; however, the importance of ATF6 in cancer remains poorly deciphered. We observed elevated ATF6 transcriptional activity in several cancers including colorectal carcinoma (CRC). Genetic silencing or small molecule inhibition of ATF6 blocked cell cycle progression and reduced viability of several human CRC cell lines in vitro and disrupted tumor progression in vivo. Unexpectedly, ATF6 interference also disabled Myc and Wnt signaling and reduced stemness. ATF6 inhibition attenuated growth of organoids derived from malignant but not normal human intestinal tissue, reducing Wnt-pathway activity and driving cellular differentiation. Wnt-surrogate agonism rescued the growth inhibitory phenotype of ATF6 interference. Our findings identify ATF6 as an unexpected facilitator of oncogenic Wnt signaling in CRC.

2024-08-12 | MSV000095581 | MassIVE

KMT9 controls growth and stemness of colorectal cancer [single-cell RNA-seq]

Project description:The aim of the study is to identify cell-specific KMT9a target genes in AOMDSS tumour organoids

2021-11-29 | GSE150505 | GEO

ATF6 promotes colorectal cancer growth and stemness by regulating the Wnt pathway

Project description:ATF6 promotes colorectal cancer growth and stemness by regulating the Wnt pathway

| PRJNA1144418 | ENA

KMT9 is an actionable target in muscle-invasive bladder cancer

Project description:Novel treatment modalities are imperative for the challenging management of muscle-invasive and metastatic BC to improve patient survival rates. The recently identified lysine methyltransferase (KMT) 9, an obligate heterodimer composed of KMT9α and KMT9β, regulates the growth of various types of tumors such as prostate, lung and colon cancer. While overexpression of KMT9α was previously observed to be associated with aggressive basal-like MIBC in an analysis of patients’ tissue samples, a potential functional role of KMT9 in this type of cancer has not been investigated to date. In this study, we show that KMT9 regulates proliferation and migration of various MIBC cell lines with different genetic mutations. KMT9α depletion results in differential expression of genes involved in the regulation of the cell cycle, cell adhesion and migration. Reduced cell proliferation upon KMT9α depletion is also observed in Pten/Trp53 knockout bladder tumor organoids, which cannot be rescued with an enzymatically inactive KMT9α mutant. In accordance with the idea that the catalytic activity of KMT9 is required for the control of cellular processes in MIBC, a recently developed small molecule inhibitor of KMT9 (KMI169) also impairs cancer cell proliferation. Since KMT9α depletion also restricts the growth of xenografts in mice, our data suggest that KMT9 is an actionable novel therapeutic target for the treatment of MIBC.

2024-05-01 | GSE255344 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data